Osteosarkome bei Kindern und Jugendlichen

Literatur

• 1 Fletcher C DM, Unni K, Mertens K. WHO-Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon: IARC Press; 2002
• 2 Bielack S, Machatschek J N, Flege S, Jürgens H. Delaying surgery with chemotherapy for osteosarcoma of the extremities.  Expert Opin Pharmacother. 2004;  5 243-1256
• 3 Kim H J, Chalmers P N, Morris C D. Pediatric osteogenic sarcoma.  Curr Opin Pediatr. 2010;  22 61-66
• 4 Hogendoorn P C, Athanasou N, Bielack S et al. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.  Ann Oncol. 2010;  21 204-213
• 5 Sobin L H, Wittekind C. UICC TNM Classification of Malignant Tumours. 6th ed. New York: Wiley; 2002
• 6 Bielack S, Kempf-Bielack B, Delling G et al. Prognostic factors in high grade osteosarcoma of the extremities or trunk: an analysis of 1.702 patients treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols.  J Clin Oncol. 2002;  20 776-790
• 7 Kager L, Zoubek A, Pötschger U et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.  J Clin Oncol. 2003;  21 2011-2018
• 8 Huvos A. Bone tumors: diagnosis, treatment and prognosis, 2nd ed. Philadelphia: WB Saunders; 1991
• 9 Salzer-Kuntschik M, Brand G, Delling G. Bestimmung des morphologischen Regressionsgrades nach Chemotherapie bei malignen Knochentumoren.  Pathologie. 1983;  4 135-141
• 10 Bielack S, Kempf-Bielack B, Schwenzer D et al. Neoadjuvante Therapie des lokalisierten Osteosarkoms der Extremitäten.  Klin Pädiatr. 1999;  211 260-270
• 11 Goorin A, Harris M, Bernstein M et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: A pediatric oncology group trial.  J Clin Oncol. 2002;  20 426-433
• 12 Marina N, Bielack S, Whelan J et al. International collaboration is feasible in trials for rare conditions: The EURAMOS experience.  Cancer Treat Res. 2010;  152 339-353
• 13 Widemann B C, Balis F M, Kempf-Bielack B et al. High-dose methotrexate-induced nephrotoxicity: incidence in osteosarcoma. Patients, treatment and outcome.  Cancer. 2004;  100 2222-2232
• 14 Goorin A M, Schwartzentruber D J, Devidas M et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651.  J Clin Oncol. 2003;  21 1574-1580
• 15 Rosen G, Caparros B, Huvos A G et al. Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy.  Cancer. 1982;  49 1221-1230
• 16 Enneking W E, Spanier S S, Goodmann M A. A system for the surgical staging of musculo-skeletal tumors.  Clin Orthop. 1980;  153 106-120
• 17 Abed R, Grimer R. Surgical modalities in the treatment of bone sarcoma in children.  Cancer Treat Rev. 2010;  36 342-347
• 18 Bielack S, Jürgens H, Jundt G et al. Osteosarcoma: The COSS Experience.  Cancer Treat Res. 2010;  152 289-308
• 19 Machak G N, Tkachv S I, Solovyev Y N et al. Neoadjuvant Chemotherapy and Local Radiotherapy for High-Grade Osteosarcoma of the Extremities.  Mayo Clin Proc. 2003;  78 147-155
• 20 DeLaney T F, Park L, Goldberg S I et al. Radiotherapy for local control of osteosarcoma.  Int J Radiat Oncol Biol Phys. 2005;  61 492-498
• 21 Anderson P. Samarium for osteoblastic bone metastases and osteosarcoma.  Expert Opin Pharmacother. 2006;  7 1475-1486
• 22 Ferrari S, Briccoli A, Mercuri M et al. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival.  J Clin Oncol. 2003;  21 710-715
• 23 Kempf-Bielack B, Bielack S, Jürgens H et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS).  J Clin Oncol. 2005;  23 559-568
• 24 Lewis I J, Nooij M A, Whelan J et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: A randomized phase III trial of the European Osteosarcoma Intergroup.  J Natl Cancer Inst. 2007;  99 112-128
• 25 Hillmann A, Hoffmann C, Gosheger G et al. Malignant tumor of the distal part of the femur or the proximal part of the tibia: endoprosthetic replacement or rotationplasty. Functional outcome and quality of life measurements.  J Bone Joint Surg Am. 1999;  81 462-468
• 26 Muller C R, Smeland S, Bauer H C et al. Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series.  Acta Oncol. 2006;  44 475-480
• 27 Meyers P A, Schwartz C L, Krailo M et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.  J Clin Oncol. 2005;  23 2004-2011
• 28 Meyers P A, Schwartz C L, Krailo M et al. Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival. A report from the Children’s Oncology Group.  J Clin Oncol. 2008;  26 633-638
• 29 Kager L, Pötschger U, Bielack S. Review of mifamurtide in the treatment of patients with osteosarcoma.  Ther Clin Risk Manag. 2010;  6 279-286
• 30 Scotlandi K, Picci P, Kovar H. Targeted therapies in bone sarcomas.  Curr Cancer Drug Targets. 2009;  9 843-853